Are there updated timelines or enrollment targets for the Chagas disease clinical program?

Answer

The AN2 Therapeutics press release does not provide any new timing milestones or patient‑enrollment goals for its Chagas disease program. The statement only notes that the program “continues to see momentum” and that the company is “advancing its boron‑chemistry pipeline,” but it stops short of specifying when the next trial phase is expected to start, how many subjects will be recruited, or when data read‑outs are anticipated.

Trading implications

• Limited catalyst impact – Because no concrete enrollment targets or trial‑start dates were added, the market has little new forward‑looking information to price in. The stock is likely to remain driven by broader portfolio dynamics (e.g., other boron‑chemistry programs) rather than by the Chagas effort alone.
  
• Watch for follow‑up disclosures – Analysts and investors should monitor upcoming SEC filings (e.g., 8‑K updates or 10‑Q filings) and conference calls for any forthcoming details on the Chagas timeline. A clear enrollment target or a projected data‑readout date would be a bullish catalyst, while further delays could pressure the share price.
  
• Positioning – In the short term, the lack of a new milestone keeps the risk/reward profile unchanged. If you are already long, maintain the position but stay alert for any future update that could trigger a price move. If you are short, the absence of a concrete timeline reduces the upside of a catalyst‑driven decline, so a short position would still be speculative.
  

Bottom line: No updated timelines or enrollment targets have been disclosed for the Chagas disease program, so the current market view remains unchanged until the company releases more specific trial‑progress information. Keep a close eye on forthcoming regulatory or investor‑relations communications for the next catalyst.